drugset
drugset / Trial / NCT01889719

A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR

NCT01889719 ↗

Phase 1 Completed 14 enrolled Rockefeller University
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This trial will investigate whether immunizations with an MVA recombinant HIV vaccine are safe and whether they will boost immune responses generated by immunizations with a dendritic cell (DC) targeted protein vaccine, DCVax-001, plus poly ICLC in healthy HIV-uninfected volunteers.

Timeline

Start
2014-01
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject MVA-CMDR Vaccine — Other

Indications

HIV infectious disease